Merit Medical's Q2 Beat Was Real-But 55% Margins May Not Stick

Merit Medical delivered a real Q2 beat, but durability is the real question

Merit Medical beat on both revenue and earnings. $418.8 million in revenue, up 10% year over year, plus $1.19 of Q2 EPS versus $1.01 last year, is a genuine beat. The key question now is less about survival and more about whether this earnings recovery can hold.

The improvement is broad enough to matter. Organic growth was the highest in three years, gross margin reached 55.8%, non-GAAP operating margin rose to 22.6%, and management raised full-year 2026 revenue and non-GAAP EPS guidance. That points to a healthier business, not just a one-off accounting improvement.

Still, this should be treated as a strong quarter rather than final proof of a permanent margin upgrade. A $6.9 million in tariff refunds helped profitability, and management also warned of typical summer moderation in procedure volumes. The job now is to see whether the operating gains are durable or whether the second quarter was the peak expression of this recovery.

Demand breadth looks credible; margin quality needs another quarter of proof

Merit posted 9% organic constant-currency growth, which is the kind of demand signal investors should respect. It was not driven by a single niche: Foundational product sales increased 6% while therapeutic product sales increased 14%. That suggests the core portfolio is still broadly useful across indications and procedures.

The OEM rebound also looks constructive. Total OEM sales increased 15% year over year, and management tied that recovery to previous destocking trends ending and new customer agreements. In practical terms, that suggests customers are buying again rather than simply working through leftover inventory.

Execution also appears to be playing a role. Management said margin improvement came from manufacturing shifts to Tijuana, more automation, and better logistics, including a shift to ocean freight. Those are concrete operating changes, not just favorable short-term pricing.

What likely is durable

• Broad-based organic demand across core categories.
• A recovering OEM channel.
• Operating improvements in manufacturing and logistics that could support better structure over time.

What needs caution

• Reported gross margin was 55.8%, but excluding $6.9 million in tariff refunds, it was 54.2%.
• Reported non-GAAP EPS was $1.19, while excluding the after-tax benefit from tariff refunds of approximately $0.09, EPS was $1.10.
• Management flagged summer procedure moderation and a full-year tariff impact that could pressure the back half.

That is why the cleaner benchmark is the ex-refund base. If Merit can hold much of that operating leverage after the tariff-refund boost fades, the recovery is real. If not, investors may decide the second quarter was unusually favorable rather than representative of a new plateau.

Stock setup still allows upside if the recovery proves repeatable

The valuation backdrop is still reasonable because shares are near the bottom of its 52-week range and below its 200-day simple moving average. That is not an exciting setup, but it does mean the stock does not need a perfect story to rerate. It needs another quarter or two that reinforces the recovery.

What would confirm the story

• Organic growth remains healthy, even if it is not as strong as Q2.
• Product mix stays broadly balanced rather than relying on one category.
• Margins stay close to the ex-refund level rather than drifting back toward prior-year structure.

What would weaken the thesis

• Growth slows sharply once the normalization after destocking fades.
• Tariff refunds or logistics gains prove mostly one-quarter beneficial.
• Guidance gains are driven more by recovery effects than by durable demand and cost improvement.

If the next reports clear that checklist, Merit Medical can start to shift from "good quarter" to "credible recovery." If not, the market may conclude that Q2 2026 was simply its best near-term expression.